RxDoctor Payments Data

Raghav Mohindra, MD

Geriatric Medicine · Prescott Valley, AZNPI 1427210426

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,384 of the $16,365 with a category attached, or 87.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,618 and has fallen 74.9% since, to $907 in 2025. Among geriatric medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,365in general payments, 2019–2025

Across 779 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Modernatx, Inc.$1K
  • Abbott$984
  • GSK$894
  • Astellas Pharma US Inc$810
  • plus $8K from 54 others
$1,946,642in research payments, 2019–2025

Across 44 payments — averaging $44,242 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.9M

What the payments were for

  • Travel & lodging$1,81511%
  • Food & beverage$14,38488%
  • Education$1181%
  • Entertainment$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca46$2,312
AbbVie(2 entities)120$1,733
Modernatx, Inc.4$1,372
Abbott38$984
GSK67$894
Astellas Pharma US Inc35$810
Sunovion Pharmaceuticals Inc.46$765
Pfizer44$653
Johnson & Johnson(2 entities)30$533
Amgen(2 entities)32$511
Boehringer Ingelheim24$475
Novo Nordisk29$397
Amarin Pharma, Inc.32$368
Watermark Medical, Inc.2$310
Sanofi-aventis U.S. LLC19$279
Eisai Inc.16$263
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$247
Takeda Pharmaceuticals U.S.A., Inc.17$242
Nestle Healthcare Nutrition Inc.10$204
Endologix LLC1$199
Medtronic(3 entities)6$186
Dexcom, Inc.9$162
Philips North America LLC8$158
Merck10$152
Kowa Pharmaceuticals America, Inc.11$146
Otsuka America Pharmaceutical, Inc.8$142
Radius Health, Inc.5$141
Lilly USA, LLC8$131
UCB, Inc.8$128
Novartis7$117
Teva Pharmaceuticals USA, Inc.7$112
Bayer5$85
Pacira Therapeutics, Inc.3$72
Almatica Pharma LLC3$59
Organogenesis Inc.3$56
Lundbeck LLC3$52
Sumitomo Pharma America, Inc.2$51
Optos, Inc.2$48
Biotronik NRO, Inc.2$46
Neurelis, Inc.3$44
Biohaven Pharmaceuticals, Inc.2$43
Seqirus USA Inc2$43
Aimmune Therapeutics, Inc.2$38
Xeris Pharmaceuticals, Inc.2$36
Paratek Pharmaceuticals, Inc.2$30
GE HealthCare1$28
Bard Peripheral Vascular, Inc.1$28
Lucid Diagnostics Inc.1$27
Exact Sciences1$27
Ironwood Pharmaceuticals, Inc2$26
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$25
RGH Enterprises LLC1$24
Corium, LLC2$23
Globus Medical1$23
Smith+Nephew2$23
Nevro Corp.1$23
IBSA Pharma Inc.1$22
Axonics, Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$19
Ardelyx, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,365 in reported general payments places this provider in the 95th percentile of 75 geriatric medicine providers in Arizona.

See all geriatric medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$264,994
Medicare patients
388
Services billed
2,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$35,471
MounjaroTirzepatide29$33,985
LinzessLinaclotide21$19,821
XareltoRivaroxaban11$11,075
MyrbetriqMirabegron11$9,424
Midodrine Hcl12$1,971
Levothyroxine Sodium140$1,725
Pantoprazole Sodium108$1,310
Gabapentin68$1,237
Rosuvastatin Calcium123$1,018
Metoprolol Succinate71$826
Losartan Potassium99$803
Atorvastatin Calcium75$790
Albuterol Sulfate HfaAlbuterol Sulfate25$729
Duloxetine Hcl22$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$653$35,47132 claims
Lilly USA, LLCMounjaro$131$33,98529 claims
AbbVieLinzess$1,733$19,82121 claims
Johnson & JohnsonXarelto$533$11,07511 claims
Astellas Pharma US IncMyrbetriq$810$9,42411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 geriatric medicine providers in Arizona.

Other geriatric medicine in Prescott Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →